Professor Raphael Mechoulam, also known as the “father of cannabis research,” recently revealed his latest discovery, Cannabidiolic Acid Methyl Ester (EPM301). The introduction of this new proprietary compound (completely stable, acid-based synthetic cannabinoid molecules) has sparked a wave of enthusiasm for the future of medical cannabis.
The link in question was introduced to the world in collaboration with EPM, a global biotechnology company based in the United States, designed to bridge the gap between cannabis and the pharmaceutical industry.
Cannabidiolic Acid Methyl Ester EPM301
During the recent conversation, CEO Reshef Swisa and Dr. Mechoulam’s journey behind this revolutionary process and its importance to the development of cannabidiol as a drug.
“EPM has developed a method for working with the original substances in cannabis,” said the professor. “While everyone is talking about THC and CBD, these cannabinoids are actually a minor substance. They only appear later in the system.
“Originally there was an acid found in the plant and these acids are these mysterious worlds of compounds that are much stronger than cannabinoids,” he added.
However, these cannabidiol acids have been unstable and therefore unusable in drug development.
Mechoulam’s recent discovery is based on the development of a method that allows acids to be modified to be stable enough to be used on a larval scale. This opens the door to other pharmaceutical experiments, the professor said.
“We take cannabidiolic acid and stabilize it with a simple chemical process called esterification. Then the compound is stable,” Swisa said.
Then the team began studying the activity of this compound and found that this particular compound causes anxiety suppression and nausea suppression, he continued, adding that this could make a big difference in children. Cancer patients receiving chemotherapy, as well as patients with IBD (inflammatory bowel disease) or psoriasis.
INNOVATE AT 88
CBD and THC have long been known to help treat a long list of illnesses ranging from inflammation and anxiety to depression and nausea.
In fact, Mechoulam was probably the foremost scientist who enlightened the active ingredients of the cannabis plant in the 1960s when his work at the Weizmann Institute led to the discovery of the human endocannabinoid system, the leading “father of cannabis research”
However, the 88-year-old researcher’s recent discovery shows that cannabidiolic acid is a much more potent compound than CBD or THC – with no known negative side effects.
“We urgently need new drugs for various diseases, and some of the available drugs are quite good but ultimately cause side effects,” he said, referring to most unnatural Pharma drugs, which are semi-synthetic at best.
“Two groups of compounds must be replaced today: steroids and opioids. We believe that cannabis has the ability to introduce substitutes to these families. “
An alternative to steroids and opioids.
While CBD has been considered as an alternative to addictive prescription drugs for several years, the EPM patent for the use of cannabidiolic acid is the first to demonstrate that these drugs can be essentially replaced without major changes. its effectiveness
“We are not only comparing our compound with cannabinoids, but also with existing drugs that are used today,” said Mechoulam. “For example, at IBD we compare our compounds with two conventional products: one is prednisone (the steroid) and the other is a biological medicine. In both cases we were able to demonstrate that the activity of our compound is very similar to that of the common product. “
THE INVESTIGATOR IS OPTIMISTIC ABOUT THE FUTURE.
“I sincerely hope that someday in the next few years we will be launching a derivative of cannabidiol acid, as well as CBD itself.”
However, he also warned about the importance of proper classification and regulation of drugs for medical use to avoid undesirable side effects.
“Companies must be careful when taking compounds and claiming therapeutic products. You must do this in accordance with regulations to create a unified language … because people confuse recreational use with medical use and don’t necessarily seek a specific indication with a specific dose, “he said.